The present invention addresses the problem of providing a method for transparentizing a biological specimen and a kit for transparentizing a biological specimen, with which it is possible to transparentize a biological specimen quickly and with which there is little composition deformation. The present invention provides a method for producing a transparentized biological specimen, the method including a step (1) for treating a transparentization substance, which is a biological specimen, with a transparentizing/decolorizing liquid to obtain a transparentized substance that was transparentized. The transparentizing/decolorizing liquid includes (a) acid amide and (b) one or more selected from the group consisting of benzyl alcohol, glycol ether, and n-butanol. The present invention also provides a kit for producing a transparentized biological specimen, the kit including a transparentizing/decolorizing liquid that includes (a) acid amide and (b) one or more selected from the group consisting of benzyl alcohol, glycol ether, and n-butanol.
This invention provides a method for preparing dendritic cells from monocytes using a platelet lysate. This invention also provides a method for preparing cytotoxic dendritic cells from monocytes comprising performing non-adhesion culture of monocytes separated from the peripheral blood using a serum-free medium containing a human platelet lysate (HPL), GM-CSF, and PEGylated interferon α and performing further non-adhesion culture with the addition of prostaglandin E2 and OK432.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A stethoscope system comprising: a plurality of sensors for collecting auscultatory sounds; and a controller which detects a first heart sound and a second heart sound of heart sounds based on a volume of the auscultatory sounds which are collected by the plurality of sensors.
FERROTEC MATERIAL TECHNOLOGIES CORPORATION (Japan)
KANAZAWA INSTITUTE OF TECHNOLOGY (Japan)
KANAZAWA MEDICAL UNIVERSITY (Japan)
Inventor
Shintani Kazuhiro
Kaneuji Ayumi
Soda Sachio
Eto Shunichi
Kouno Hitoshi
Abstract
A ceramic biological material according to one aspect is composed of a sintered body comprising silicon nitride and a sintering aid and having flexural strength of 1196 MPa or more. This ceramic biological material may contain silicon nitride in an amount of 88.0 to 98.0% by mass. This ceramic biological material may contain the sintering aid in an amount of 2.0 to 12.0% by mass.
The purpose of the present invention is to provide a method for preparing a dendritic cell from a monocyte using a platelet lysate. Provided is a method for preparing a dendritic cell having cytotoxicity from a monocyte, the method comprising culturing a monocyte separated from peripheral blood by non-adhesive culture using a serum-free culture medium containing a human platelet lysate (HPL), GM-CSF and PEG conjugated interferon-α, adding prostaglandin E2 and OK432 to the resultant culture, and further culturing the resultant mixture by non-adhesive culture.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
An object of the present invention is to provide a molecular targeted drug effective for diffuse gastric cancer. According to the present invention, there is provided a pharmaceutical composition for treating diffuse gastric cancer in a patient, which comprises an EGF receptor inhibitor having an ErbB1 inhibitory activity and an ErbB4 inhibitory activity. According to the present invention, there is provided the aforementioned pharmaceutical composition for use in a combination therapy with an anti-VEGF receptor 2 antibody and/or a cMET inhibitor. According to the present invention, there is provided a method for treating diffuse gastric cancer in a patient, which comprises the step of administering an EGF receptor inhibitor having an ErbB1 inhibitory activity and an ErbB4 inhibitory activity to the patient.
To provide a therapeutic agent to achieve highly effect on diffuse gastric cancer typified by scirrhous gastric cancer and a therapeutic agent to achieve highly effect on cMet gene-amplified gastric cancer. The problem is solved by a therapeutic agent for treating diffuse gastric cancer containing (i) an MEK inhibitor or (ii) an MEK inhibitor and an mTOR inhibitor or a therapeutic agent for treating cMet gene-amplified gastric cancer containing (i) an MEK inhibitor or (ii) an MEK inhibitor and an mTOR inhibitor.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
The present invention pertains to a method for creating reprogramed cells from somatic cells without gene introduction. The method includes a step (a) for culturing somatic cells in a medium containing a histone deacetylase inhibitor, and a step (b) for culturing the cells cultured in step (a) in a medium containing an OCT3/4 transcription stimulating factor to create reprogrammed cells.
The present invention addresses the problem of providing a medium for efficiently inducing differentiation of dendritic cells and a method for producing dendritic cells using the medium. The present invention provides a dendritic cell differentiation-inducing medium that contains at least one member selected from the group consisting of a) a granulocyte-macrophage colony-stimulating factor, b) a ROCK inhibitor, and c) an FGFR inhibitor and an MAPK/ERK kinase inhibitor. The present invention provides a method for producing a dendritic cell population, said method comprising a step for culturing a bone marrow cell sample or a peripheral blood sample in a medium to give a dendritic cell population. The present invention provides a method for producing a dendritic cell vaccine, said method comprising a step for culturing a bone marrow cell sample or a peripheral blood sample in a dendritic cell differentiation-inducing medium to give a dendritic cell population, and a step for preparing the dendritic cell population obtained in the aforesaid step into a dendritic cell vaccine. The present invention provides a dendritic cell population that contains CD11c-positive and MHC class II-positive cells (CD11c+MHCIIhicells) at a ratio of 30% or higher relative to the cell population, wherein, in the CD11c+MHCIIhi cells, the expression of at least one gene, from among C/EBPα-, PPARγ- and TGF-β-related genes, is increased.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
KANAZAWA MEDICAL UNIVERSITY (Japan)
Inventor
Kondo Takashi
Abe Hitoshi
Kurachi Masayoshi
Suzuki Michio
Uehara Takashi
Abstract
A compound represented by formula (1) or a pharmaceutically acceptable salt thereof can be used as an active ingredient of a drug for central nervous system diseases or as a candidate compound for a precursor of said active ingredient. In formula (1), R1, R2, and R3each independently represent a substance selected from the group consisting of a hydrogen atom, a hydroxy group, and an alkoxy group having 1-6 carbon atoms, and at least one of R1, R2, and R3 is a hydroxy group.
The present invention addresses the problem of providing a molecular targeted drug that is efficacious for diffuse-type gastric cancer. Provided is a pharmaceutical composition for treating diffuse-type gastric cancer in a patient, said pharmaceutical composition comprising an EGF receptor inhibitor having ErbB1 inhibitory activity and ErbB4 inhibitory activity. Also provided is the aforesaid pharmaceutical composition that is to be used in a combination therapy with an anti-VEGF receptor 2 antibody and/or a cMET inhibitor. Also provided is a method for treating diffuse-type gastric cancer in a patient, said method comprising a step for administering the patient with an EGF receptor inhibitor having ErbB1 inhibitory activity and ErbB4 inhibitory activity.
An antibacterial member that maintains a high antibacterial property and a high osteoconductive property for a long duration is provided. The antibacterial member includes a DLC film (F-DLC film) 40 containing fluorine at least partially or entirely on an outermost surface of a base material 10. The F-DLC film has an element ratio (F/(F+C)) of 17% to 72% and a nanoindentation hardness of 2,000 MPa to 16,000 MPa. This maintains wear resistance and close contact, and obtains an antibacterial member that maintains a high antibacterial property and a high osteoconductive property for a long duration. The F-DLC film does not necessarily need to cover the entire outermost surface of the base material but may be disposed in a mottled pattern.
[Abstract] [Problem to be solved] To provide a treatment agent having a high effect on diffuse gastric cancer represented by scirrhous gastric cancer, and a treatment agent having a high effect on cMet gene amplification gastric cancer. [Solution] The aforementioned problem is solved by a diffuse gastric cancer treatment agent and a cMet gene amplification gastric cancer treatment agent including (i) an MEK inhibitor, or including (ii) an MEK inhibitor and an mTOR inhibitor. No selected drawing
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Provided is an antibacterial member capable of maintaining a high antibacterial effect and excellent osteoconductive properties over a long period of time. The antibacterial member according to the present invention, which is provided with a fluorine-containing DLC film (F-DLC film) 40 on at least a part or the entire of the outermost surface of a base material 10, is characterized in that the element ratio (F/F+C) of the F-DLC film is 17-72% and the nanoindentation hardness is 2,000-16,000 MPa. Thus, an antibacterial member capable of sustaining a high wear resistance and good adhesion and maintaining a high antibacterial effect and excellent osteoconductive properties over a long period of time can be obtained. The F-DLC film does not necessarily cover the entire outermost surface of the base material but may be disposed in spots thereon.
The present invention relates to a culture vessel which can be broadly applied to culture, regeneration, manufacture, observation and the like of targets such as cells, organs, and microorganisms. In the culture vessel of the present invention, a first vessel 10 and a second vessel 20 each being a close-bottom, open-top vessel are provided. In the first vessel 10 and the second vessel 20, a sideways-facing opening 12 and a sideways-facing opening 22 are formed. The opening 12 and the opening 22 communicate in a watertight manner when the openings 12, 22 are connected face to face.
A method and a kit are provided to produce a biological clear specimen within a short time and with a wide variety of biological specimens. The method includes the following steps: (1) treating a material to be cleared with an aqueous fixing solution containing paraformaldehyde or the like, a nonionic surfactant, an alkali, and optionally a buffering agent; (2) treating the material from step (1) or a conventionally fixed material with an aqueous clearing accelerator solution containing a nonionic surfactant and an alkali; and (3) treating the material produced in step (1) or (2) with an aqueous preservation solution containing a nonionic surfactant and a polyhydric alcohol. In each of the steps, the nonionic surfactant is present at a concentration of 1% or more. The kit includes solutions used in each of the steps of the method.
The present invention pertains to a culture vessel that can be broadly applied to the culture, regeneration, manufacture, observation, and the like of targets such as cells, organs, and microorganisms. In this culture vessel, a first vessel (10) and a second vessel (20) which are closed-bottom, open-top vessels, are provided; a sideways-facing opening (12) and a sideways-facing opening (22) are formed in the first vessel and second vessel (10, 20), respectively; and when the openings (12, 22) are connected face to face, the openings (12, 22) communicate in a watertight manner.
The present invention pertains to a culture vessel that can be broadly applied to the culture, regeneration, manufacture, observation, and the like of targets such as cells, organs, and microorganisms. In this culture vessel, a first vessel (10) and a second vessel (20) which are closed-bottom, open-top vessels, are provided; a sideways-facing opening (12) and a sideways-facing opening (22) are formed in the first vessel and second vessel (10, 20), respectively; and when the openings (12, 22) are connected face to face, the openings (12, 22) communicate in a watertight manner.
[Problem] To provide a method for strongly induce enucleation within a short period of time and a method for improving the survival rate of enucleated erythrocytes. [Solution] The present invention was completed by finding "incubation of erythroblasts under low-oxygen conditions exhibits an effect of advancing the starting timing of enucleation, an effect of removing nuclei, an effect of promoting the induction of enucleation and an effect of improving the survival rate of enucleated erythrocytes".
The present invention is a method for building a three-dimensional model of an organ, employing any of the following. If a subsequently selected pair of points to be linked both return to a starting point, a seventh procedure is terminated. Depending on the case, candidate points adjacent to one point to be linked and another point to be linked are selected as the next pair of points to be linked. The distance from the one point to be linked to a candidate point adjacent to the other point to be linked and the distance from the other point to be linked to a candidate point adjacent to the one point to be linked are calculated by three-dimensional space conversion, taking into consideration the distance between layers. The two points having the shorter distance therebetween among the two calculated distances are selected as the next pair of points to be linked.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
Provided are: a method and a kit for transparentizing a biological specimen, which enable the transparentization within a short time and by which a wide variety of biological specimens can be transparentized; and a method and a kit for preserving a transparentized biological specimen. A method for producing a transparentized biological specimen, comprising steps as mentioned in items (A) to (C). (A) Step (1) of treating a material to be transparentized with a fixing solution that is an aqueous solution containing paraformaldehyde or the like, a nonionic surfactant (at a concentration of 1% or more) and an alkali and optionally containing a buffering agent to produce the material that is transparentized is involved. (B) Step (2) of treating the material that is produced in step (1) or a material to be transparentized which is produced by a conventional fixing method with a transparentization accelerator solution that is an aqueous solution containing a nonionic surfactant (at a concentration of 1% or more) and an alkali to produce the material that is transparentized is involved. (C) Step (3) of treating the material produced in step (1) or (2) with a preservation solution that is an aqueous solution containing a nonionic surfactant (at a concentration of 1% or more) and a polyhydric alcohol to produce the material that is transparentized is involved. A kit which can be used in the method.
The manufacturing method for a heart correction net according to the present invention involves carrying out preliminary analysis, by means of steps one to six, before manufacturing a heart correction net which will be actually attached to the heart of a patient, and then after the analysis, manufacturing the heart correction net which will be actually attached to the heart of a patient, by means of steps seven to thirteen. In step eleven, the homothetic ratio at which the contact pressure on the heart will be within a prescribed numeric range is estimated on the basis of the relationship between the homethetic ratio and the contact pressure and the volume of an accommodated-object, analyzed in step six. In step twelve, either correction for enlargement or correction for reduction is applied to data for a pattern on the basis of the homothetic ratio estimated in step eleven and data for a pattern generated in step nine.
The heart correction net according to the present invention is attached to the outside of a heart. The heart correction net includes, within the entirety of an area surrounding the ventricles, a first area which is an area that is part of an area on the right atrium side, and a second area which is an area on the left atrium side and which includes an area on the right atrium side that surrounds the perimeter of the first area. The first area of the heart correction net is configured so as to have a contact pressure on the heart during auxocardia which is lower than that of the second area.
Provided is a manufacturing method for a heart correction net, the method comprising: a first step in which a cross-section image of a heart is captured in a layer direction which spans the apex and the base of the heart; a second step in which contour lines for the heart are extracted from the cross-section image; a third step in which division points are set, on the contour lines, in the peripheral direction of the heart, on a three-dimensional image which has been re-constructed on the basis of the contour lines; a fourth step in which the three-dimensional external surface shape of the heart is divided into a plurality of divided areas on the basis of the division points, and, whilst substantially maintaining the shape of each of the divided areas, each of the divided areas is spread across a two-dimensional plane and spread-out data is generated; a fifth step in which data for a pattern is generated on the basis of the spread-out data; and a sixth step in which the heart correction net is knitted by means of a knitting machine on the basis of the data for a pattern.
Disclosed are a novel therapeutic agent and a novel prophylactic agent for atherosclerosis, a blood cholesterol level-lowering agent, and a functional food or a food for specified health uses effective for the inhibition and/or prevention of aging of blood vessels or inflammation in blood vessels. Specifically disclosed are an inhibitor of the progression of atherosclerosis, a prophylactic agent for atherosclerosis, a blood cholesterol level-lowering agent, and a functional food and a food for specified health uses both effective for the inhibition and/or prevention of aging of blood vessels or inflammation in blood vessels, each of which comprises, as an active ingredient, a hydrolysis product of a collagen comprising at least one collagen tripeptide Gly-X-Y [wherein Gly-X-Y represents an amino acid sequence; and X and Y independently represent an amino acid residue other than Gly].
C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
27.
LIGHT EXPOSURE DEVICE FOR IMPROVING COGNITIVE SYMPTOMS AND DEPRESSION SYMPTOMS, CHAMBER HAVING LIGHT EXPOSURE DEVICE, AND LIGHTING EQUIPMENT FOR IMPROVING COGNITIVE SYMPTOMS AND DEPRESSION SYMPTOMS
A light exposure device (20) for improving cognitive symptoms and depression symptoms is characterized in imparting photostimulation to the retina by continuous flashing of a light source (21) at a frequency of 1 to 10 Hz and by photostimulation, inducing the continuous expression of Homer 1a and activation of the BK-type potassium channels in pyramidal cells of the cerebral cortex. It is possible to realize the same effect as the depression symptom-improving effect of an electroconvulsive stimulation device, and the same effect as the depression symptom-improving effect and cognitive symptom-improving effect of a transcranial magnetic stimulation device, and can be used in a home environment when compared to electroconvusion stimulation devices and transcranial magnetic stimulation devices that are limited being used for treatment at a medical institution.
A61M 21/02 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (Japan)
KANAZAWA INSTITUTE OF TECHNOLOGY (Japan)
KANAZAWA MEDICAL UNIVERSITY (Japan)
Inventor
Takamura, Yuzuru
Idegami, Kotaro
Kogi, Mieko
Takabayashi, Haruo
Abstract
Provided is a method for concentrating and collecting fetus-derived nucleated red blood cells contained in a small amount in the blood of a mother body. A method for concentrating and collecting nucleated red blood cells from the blood of a mother body, comprising (i) subjecting the blood of the mother body to first density-gradient centrifugation to collect a cell fraction containing the nucleated red blood cells, (ii) treating the cell fraction containing the nucleated red blood cells in such a manner that the density of the nucleated red blood cells can be varied in a selective manner, thereby avoiding the overlapping of the density of the nucleated red blood cells and the density of white blood cells each other, and (iii) subjecting the treated cell fraction containing the nucleated red blood cells to second density-gradient centrifugation to collect a fraction containing the nucleated red blood cells.
JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (Japan)
KANAZAWA MEDICAL UNIVERSITY (Japan)
Inventor
Kumo, Takeshi
Takamura, Yuzuru
Takabayashi, Haruo
Abstract
Provided is a chip or the like having a particulate concentrating mechanism such as a mechanism that can selectively concentrate nucleated red blood cells contained in maternal blood and derived from a fetus and can collect the concentrated liquid rich in nucleated red blood cells, and also provided is a nucleated red blood cell concentrating/collecting method. A micro-channel chip for concentrating nucleated red blood cells has an inlet-side channel, an outlet-side channel, and a separation narrow channel provided between the inlet-side channel and the outlet-side channel. The separation narrow channel has an inner wall having a dimension through which non-nucleated red blood cells easily pass and nucleated red blood cells hardly pass, and has a means for deforming or moving part of the inner wall of the channel to have a dimension through which nucleated red blood cells easily pass. The following are also provided: a method for collecting a liquid in which nucleated red blood cells obtained by using this chip are concentrated; and a micro-channel chip for concentrating particulates other than for concentrating nucleated red blood cells.
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
C12M 1/00 - Apparatus for enzymology or microbiology
C12N 5/078 - Cells from blood or from the immune system
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
G01N 37/00 - Details not covered by any other group of this subclass
30.
PROGRESSION INHIBITOR OR PROPHYLACTIC AGENT FOR ATHEROSCLEROSIS, BLOOD CHOLESTEROL LEVEL-LOWERING AGENT, AND FUNCTIONAL FOOD OR FOOD FOR SPECIFIED HEALTH USES
Disclosed are a novel therapeutic agent and a novel prophylactic agent for atherosclerosis, a blood cholesterol level-lowering agent, and a functional food or a food for specified health uses effective for the inhibition and/or prevention of aging of blood vessels or inflammation in blood vessels. Specifically disclosed are an inhibitor of the progression of atherosclerosis, a prophylactic agent for atherosclerosis, a blood cholesterol level-lowering agent, and a functional food and a food for specified health uses both effective for the inhibition and/or prevention of aging of blood vessels or inflammation in blood vessels, each of which comprises, as an active ingredient, a hydrolysate of a collagen comprising at least one collagen tripeptide Gly-X-Y [wherein Gly-X-Y represents an amino acid sequence; and X and Y independently represent an amino acid residue other than Gly].
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
31.
METHOD FOR DENUCLEATING NUCLEATED ERYTHROCYTE, AND DENUCLEATION INDUCER
Disclosed is a factor which can induce the denucleation, which is the final stage of the differentiation of an erythrocyte, within a short time. Specifically disclosed is a method for inducing the denucleation, which is the final stage of the differentiation of an erythrocyte, within a short time, which comprises adding a compound derived from proopiomelanocortin (POMC) to an undifferentiated (nucleated) erythrocyte. Also specifically disclosed is a denucleation inducer comprising the compound.
C07K 14/665 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
patents
